Max Herrmann, chief financial officer of ReViral Ltd., discusses the company's recent successful series A financing and what sets ReViral apart in antiviral development.
A fund to bridge the UK financing gap between cancer drug discovery and early treatment development is managed by Sixth Element Capital and making an innovative impact.
CEO Kate Torchilin explains how her company's platform can improve access to data and biospecimens during an interview at the recent Biotech Showcase.
Covance Xcellerate Informatics
Covance Xcellerate Insights
Covance Xcellerate Monitoring
Covance Xcellerate Trial Management
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.